News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
timothysykes.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Angiodynamics, Inc. (UG2) released its Q1 2025 earnings report, showing an actual EPS of -€0.10, beating the consensus of -€0.13 by +€0.03. However, the company missed revenue expectations, reporting €58.49M against an expected €58.88M, marking a -14.22% year-over-year decline. The earnings call took place …
Wall Street Zen has upgraded Diodes (NASDAQ:DIOD) to a "strong-buy" rating, while the broader analyst consensus remains "Buy" with a $135 price target. The company recently surpassed quarterly earnings expectations, reporting $0.70 adjusted EPS against an estimated $0.63, and saw revenues increase by 21.7% …
Diodes Incorporated (DIOD) stock rose by 6.47% after exceeding Q2 earnings expectations and providing strong Q3 guidance, driven by demand in automotive, industrial, and AI server sectors. Despite a premarket dip due to a $325M convertible notes deal, the stock reclaimed the $100 area, …
Diodes Incorporated (DIOD) director Evan Yu has filed an initial statement of beneficial ownership (Form 3), reporting direct ownership of 12,000 shares of the company's common stock. This filing establishes his equity position as an insider. The report clarifies that Yu is a director …
Biodesix director Jack W. Schuler recently purchased 15,000 shares of the company's stock for $366,991, with the stock trading near its 52-week high after a significant 200% gain. While InvestingPro suggests the stock is overvalued, analysts maintain higher price targets. This follows Biodesix's strong …
Diodes Inc (DIOD) shares dropped 9.2% to $97.19, yet GuruFocus assesses the stock as significantly overvalued by 37.8% compared to its GF Value of $70.54. Despite a strong GF Score of 80/100, reflecting robust financial health and momentum, its low valuation rank of 3/10 …
Biodesix Director Jack Schuler recently purchased 15,000 shares of BDSX stock for $367,050, increasing his direct ownership to 555,810 shares. This transaction occurred as Biodesix shares traded down 1.8% to $23.79, despite the company surpassing quarterly earnings and revenue expectations. Analysts generally have a …
Diodes Incorporated director Evan Yu was awarded 2,250 restricted stock units (RSUs) on August 12, 2026, at no cash cost, under a Rule 16b-3 Plan. These RSUs will vest in four equal installments starting May 26, 2027. Following this grant, Yu's direct ownership in …
Jack W. Schuler, a major holder and emeritus director of Biodesix Inc. (BDSX), indirectly purchased 15,000 shares of common stock on August 12, 2026. The shares were bought at a weighted average price of $24.4661 per share through the Jack W. Schuler Living Trust, …
An insider at Biodesix (BDSX) recently purchased shares valued at $366,992, as disclosed in a recent SEC filing. This transaction was published on August 13, 2026, at 05:40 pm EDT, according to MT Newswires. Biodesix specializes in diagnostic solutions, particularly for lung cancer testing …
A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have added about 8.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings …
PLANO, Texas, August 13, 2026--(BUSINESS WIRE)--Diodes Incorporated ("Diodes") (Nasdaq: DIOD), today announced it intends to offer, subject to market conditions and other factors, $325 million aggregate principal amount of Convertible Senior Notes due 2031 (the "notes") in a private placement (the "offering") only to …
Biodesix, Inc. (NASDAQ:BDSX) has received a "Moderate Buy" consensus rating from five brokerages, with an average 12-month price target of $31.33. This comes as the company exceeded quarterly expectations, reporting revenues of $26.86 million and a lower-than-expected adjusted loss per share. Insider activity also …
Biodesix reaffirmed its full-year revenue guidance of $108 million to $114 million, representing approximately 25% year-over-year growth at the midpoint, and expects to achieve positive adjusted EBITDA on a run-rate basis soon. The company highlighted growth in its Nodify CDT test, driven by commercial …
Biodesix (NASDAQ:BDSX) Director Jack Schuler recently purchased 13,900 shares of the company's stock for over $337,000, increasing his direct stake by 2.71%. The company reported better-than-expected quarterly revenue and EPS, although it remains unprofitable. Analysts maintain a "Moderate Buy" rating for Biodesix with an …
Diodes Inc (DIOD) recently saw its shares rally by 3.8% to $107.04, but GuruFocus's GF Value suggests the stock is significantly overvalued by 58.7%, with an estimated intrinsic value of $67.44. The company has a strong financial strength rating of 9/10 but a weak …
Biodesix Inc. (NASDAQ:BDSX) Director Jack W. Schuler recently acquired 27,600 shares of company stock for approximately $665,940 through two transactions on August 10 and 11, 2026. These purchases occurred as the stock trades near its 52-week high after a 257% year-to-date surge, despite InvestingPro …
Jack W. Schuler, a major shareholder and emeritus director of Biodesix Inc. (BDSX), has increased his holdings through open-market purchases made via the Jack W. Schuler Living Trust. Over two days, August 10 and August 11, 2026, Schuler acquired a total of 27,600 shares …
Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. MedTech is expected to become AngioDynamics' majority revenue source in fiscal 2027, rising from 47% of fiscal 2026 revenue. Management forecasts 12%–15% MedTech growth, driven by Auryon, mechanical thrombectomy products and …
AngioDynamics discussed its strategic pivot from a legacy catheter business to a high-growth MedTech portfolio at the Canaccord Genuity conference. The company highlighted 18% MedTech revenue growth in fiscal 2026, now comprising 47% of total revenue, and projected 12-15% MedTech growth for fiscal 2027. …
AngioDynamics, Inc. (ANGO) presented a slideshow at Canaccord Genuity's 46th Annual Growth Conference. The article, authored by SA Transcripts, highlights the company's participation in this event. SA Transcripts is responsible for publishing thousands of quarterly earnings call transcripts and other transcript-related projects on Seeking …
Wisner Baum is actively investigating claims against AngioDynamics and Navilyst Medical concerning implantable port catheters due to reported complications like infection, thrombosis, device fracture, and migration. The AngioDynamics Port Catheter MDL, centralized in California, has grown to over 400 pending actions as of July …
PLANO, Texas, August 11, 2026--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD), today announced the Company's participation in the following financial conferences: Needham Semiconductor & SemiCap 1x1 Conference Participation Date: Wednesday, August 19, 2026 Location: Virtual Jefferies Semiconductor, IT Hardware & Communications Technology Conference Participation Date: Tuesday, …
HC Wainwright has updated its Q3 2026 EPS estimates for Biodesix (NASDAQ:BDSX), lowering it to a loss of $0.75 per share, while maintaining a "Buy" rating and a $27 price target. This follows Biodesix's recent Q2 earnings report where the company surpassed analyst expectations, …
Canaccord Genuity has maintained a 'Buy' rating for Biodesix (BDSX) and increased its price target from $27.00 to $35.00, indicating strong confidence in the company's future. While analysts are optimistic about Biodesix's growth, particularly in medical diagnostics, the stock is considered modestly overvalued according …
Search by ticker symbol or company name and select a result to open its chart.